226 related articles for article (PubMed ID: 36656585)
1. Receipt of Targeted Therapy and Survival Outcomes in Patients With Metastatic Colorectal Cancer.
Koroukian SM; Booker BD; Vu L; Schumacher FR; Rose J; Cooper GS; Selfridge JE; Markt SC
JAMA Netw Open; 2023 Jan; 6(1):e2250030. PubMed ID: 36656585
[TBL] [Abstract][Full Text] [Related]
2. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
[TBL] [Abstract][Full Text] [Related]
3. Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer.
Wang C; Sandhu J; Fakih M
Oncologist; 2022 Mar; 27(2):104-109. PubMed ID: 35641204
[TBL] [Abstract][Full Text] [Related]
4. Targeted Therapy for Colorectal Cancer.
Sakata S; Larson DW
Surg Oncol Clin N Am; 2022 Apr; 31(2):255-264. PubMed ID: 35351276
[TBL] [Abstract][Full Text] [Related]
5. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
J Gastrointest Cancer; 2019 Jun; 50(2):269-275. PubMed ID: 29388061
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
7. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
8. Role of Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of Randomized Clinical Trials.
Wang JX; Wu HL; Zhu M; Zhou R
Pathol Oncol Res; 2020 Jan; 26(1):159-166. PubMed ID: 29383654
[TBL] [Abstract][Full Text] [Related]
9. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.
Rowland A; Dias MM; Wiese MD; Kichenadasse G; McKinnon RA; Karapetis CS; Sorich MJ
Br J Cancer; 2015 Jun; 112(12):1888-94. PubMed ID: 25989278
[TBL] [Abstract][Full Text] [Related]
11. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
12. Clinical Impact of Primary Tumor Location and
Sato T; Osumi H; Shinozaki E; Ooki A; Shimozaki K; Kamiimabeppu D; Nakayama I; Wakatsuki T; Ogura M; Takahari D; Chin K; Yamaguchi K
Anticancer Res; 2021 Aug; 41(8):3905-3915. PubMed ID: 34281853
[TBL] [Abstract][Full Text] [Related]
13. Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
Palmieri LJ; Mineur L; Tougeron D; Rousseau B; Granger V; Gornet JM; Smith D; Lievre A; Galais MP; Doat S; Pernot S; Bignon-Bretagne AL; Metges JP; Baba-Hamed N; Michel P; Obled S; Vitellius C; Bouche O; Saban-Roche L; Buecher B; des Guetz G; Locher C; Trouilloud I; Goujon G; Dior M; Manfredi S; Soularue E; Phelip JM; Henriques J; Vernery D; Coriat R
Oncologist; 2020 Feb; 25(2):e266-e275. PubMed ID: 32043796
[TBL] [Abstract][Full Text] [Related]
14. RAS Amplification as a Negative Predictor of Benefit from Anti-EGFR-Containing Therapy Regimens in Metastatic Colorectal Cancer.
Schrock AB; Lee JK; Sandhu J; Madison R; Cho-Phan C; Snider JW; Castellanos E; Venstrom JM; Fakih M
Oncologist; 2021 Jun; 26(6):469-475. PubMed ID: 33465286
[TBL] [Abstract][Full Text] [Related]
15. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials.
Khattak MA; Martin H; Davidson A; Phillips M
Clin Colorectal Cancer; 2015 Jun; 14(2):81-90. PubMed ID: 25666296
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
Shinozaki E; Yoshino T; Yamazaki K; Muro K; Yamaguchi K; Nishina T; Yuki S; Shitara K; Bando H; Mimaki S; Nakai C; Matsushima K; Suzuki Y; Akagi K; Yamanaka T; Nomura S; Fujii S; Esumi H; Sugiyama M; Nishida N; Mizokami M; Koh Y; Abe Y; Ohtsu A; Tsuchihara K
Br J Cancer; 2017 Nov; 117(10):1450-1458. PubMed ID: 28972961
[TBL] [Abstract][Full Text] [Related]
17. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
[TBL] [Abstract][Full Text] [Related]
18. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
19. Loss of RAS Mutations in Liquid Biopsies of Patients With Multi-Treated Metastatic Colorectal Cancer.
Albuquerque J; Neto da Silva D; Padrão T; Leal-Costa L; Bizarro R; Correia J; Baptista C; Machete M; Prazeres G; Margarido I; Fernandes G; Simões P; Timóteo T; Lopes F; Godinho J; Moreira-Pinto J; Rodrigues T; Faria A; Pulido C; Cirnes L; Teixeira JA; Passos Coelho JL
Oncologist; 2024 Mar; 29(3):e337-e344. PubMed ID: 38071748
[TBL] [Abstract][Full Text] [Related]
20. Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.
Yamada T; Matsuda A; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Koizumi M; Shinji S; Yokoyama Y; Ohta R; Yoshida H
Int J Clin Oncol; 2020 Aug; 25(8):1523-1532. PubMed ID: 32394048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
